Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Real-time Estimate Cboe BZX Other stock markets 01:10:34 13/05/2026 am IST			5-day change	1st Jan Change
18.99 ^USD	+1.77%		+7.75%	+8.06%

04/05	U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower	RE
01/05	Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q1 Adjusted Loss $0.15 per Share, vs. FactSet Est of $-0.17	MT

Transcript : Summit Therapeutics Inc., Q1 2025 Earnings Call, May 01, 2025

Published on 05/02/2025 at 01:45 am IST - Modified on 05/02/2025 at 02:00 am IST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Hello, and welcome to the Summit Therapeutics Q1 2025 Earnings Conference Call.

I would now like to turn the call over to

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Summit Therapeutics Inc.

04/05	U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower	RE
01/05	Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q1 Adjusted Loss $0.15 per Share, vs. FactSet Est of $-0.17	MT
01/05	Summit Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
27/04	Acurx Pharmaceuticals, Inc., Adiso Therapeutics, Inc., Summit Therapeutics Inc., Finch Therapeutics Group, Inc. and Astrazeneca plc Announces Clostridium Difficile Infections Clinical Trial Updates	CI
27/03	Summit Therapeutics Inc. Announces Multiple Ivonescimab Data Sets from Phase III Studies in Advanced Nsclc Patient Populations to Be Featured At ELCC 2026	CI
12/03	Summit Therapeutics Inc. Presents at The Citizens Life Sciences Conference 2026, Mar-11-2026 02:15 PM
03/03	Summit Therapeutics Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 02:30 PM
24/02	Summit Therapeutics Inc., Q4 2025 Earnings Call, Feb 23, 2026
24/02	Summit Therapeutics Q4 Net Loss Widens, Yearly Cash Equivalents Rise	MT
24/02	Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q4 Adjusted Loss $0.14 per Share, vs. FactSet Est of $-0.09	MT
24/02	Summit Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
09/02	Avacta appoints new chief scientific officer, plans clinical trials	AN
09/02	Avacta Therapeutics Announces Executive Changes	CI
29/01	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI
29/01	Summit Therapeutics Says US FDA Accepts BLA for Ivonescimab	MT